Loading clinical trials...

Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer | Clinical Trials | Clareo Health

RECRUITINGNA

Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer

NCT05789433•AdventHealth Translational Research Institute

Summary

The goal of this clinical trial is to quantify the effects of aerobic exercise training compared to attention control on intermuscular adipose tissue in colorectal cancer survivors.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age ≥18 years
•Histologically confirmed stage I, II, or III colon or rectal cancer
•Completed surgical resection with curative intent
•Completed other cancer-directed treatments
•Engage in \<150 minutes per week of moderate- to vigorous-intensity structured endurance exercise
•No planned major surgery during the study period
•Readiness to exercise, as determined by a modified version of the Physical Activity Readiness Questionnaire
•Ability to provide written informed consent
•Provide written approval by a qualified healthcare professional
•Willing to be randomized

Exclusion Criteria

•Evidence of metastatic or recurrent colorectal cancer
•Concurrently actively treated other (non-colorectal) cancer
•Scheduled to receive other postoperative cancer-directed treatment(s)
•Currently pregnant, breastfeeding, or planning to become pregnant within the next 24 weeks
•Currently participating in another study with competing outcomes
•Contraindications to magnetic resonance imaging
•Any dietary condition or restriction that would limit tolerance of a mixed meal challenge
•Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric, or other condition that, in the investigator's opinion, would preclude participation or successful compliance with the protocol
•Any other situation that, in the opinion of the investigator, would negatively impact subject safety or successful compliance with the protocol

Locations (1)

AdventHealth

Orlando, Florida, United States

Key Dates

Start Date

May 1, 2023

Primary Completion Date

March 1, 2027

Completion Date

March 1, 2027

Last Updated

July 3, 2025

Enrollment

ESTIMATED participants

Conditions

Colonic NeoplasmsRectal Neoplasms

Interventions

Aerobic exercise

BEHAVIORAL

Progressive stretching

BEHAVIORAL

Contacts

Justin C. Brown, Ph.D.

CONTACT

407-303-5600 Justin.Brown4@AdventHealth.com

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

NCT06662786

Colorectal Neoplasms

View study

RECRUITINGPHASE1

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

NCT06663319

Colorectal NeoplasmsGastrointestinal Neoplasms

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 3, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer

Inclusion Criteria

Exclusion Criteria

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer

DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition